An abnormal plasma antithrombin with no apparent affinity for heparin.
ABSTRACT Congenital antithrombin abnormality was found in several members of a French family. No history of thrombotic episodes was associated with this abnormality. Plasma antithrombin concentration as well as the rate of thrombin inactivation by defibrinated plasma in the absence of heparin were normal. However, the heparin cofactor activity was decreased by about 50% in plasma of affected patients. Accordingly, about half the amount of plasma antithrombin did not bind to gel bound heparin. Moreover the crossed immunoelectrophoretic pattern in the presence of heparin demonstrated two peaks of antithrombin, the slower one migrating as normal antithrombin when heparin was omitted from the first agarose gel. It was concluded that molecular alteration of the antithrombin molecule seemed to affect only the heparin binding site thus preventing from any rate enhancement of thrombin inactivation.
- [Show abstract] [Hide abstract]
ABSTRACT: An antithrombin III (AT III) functional defect (AT III Charleville) was discovered in a patient presenting with recurrent venous thrombosis. Both anti-activated factor X (anti Xa) and antithrombin activity were decreased, in the absence and in the presence of heparin, while protein concentration was normal in an immunological assay. The abnormal AT III copurified with functional AT III using insolubilized heparin affinity chromatography. Polyacrylamide gel electrophoresis (PAGE) and high pressure liquid chromatography (HPLC) on a TSK column suggest that AT III Charleville forms unstable complexes with thrombin from which a modified protein is rapidly released.Thrombosis Research 10/1985; 39(5):559-70. DOI:10.1016/0049-3848(85)90236-1 · 2.43 Impact Factor
- Nucleic Acids Research 04/1986; 14(5):2408. DOI:10.1093/nar/14.5.2408 · 9.11 Impact Factor
- Thrombosis Research 02/1987; 45(1):115-21. DOI:10.1016/0049-3848(87)90263-5 · 2.43 Impact Factor